null

null

null

null

null

null

null

null

null

Near-zero debt; cash-funded operations with ~$200M+ cash runway; 20% rate rise has negligible direct interest expense impact

Minimal debt exposure; rate sensitivity primarily via discount rate effect on DCF valuation and higher cost of future equity raises

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) US-China tension risk for cell therapy manufacturing reagents/vectors; 2) Single-source viral vector CDMO concentration risk

Pre-revenue clinical stage; no meaningful international revenue; sovereign currency devaluation exposure is essentially zero currently

Operations primarily US-based (South San Francisco); clinical trials in limited international sites; negligible FX revenue exposure

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or dual CDMO partners for lentiviral vector manufacturing; substitution would take 12-24+ months and jeopardize trials

Clinical-stage biopharma; no cloud-infrastructure revenue dependency; AWS/GCP termination would disrupt data systems but not core therapy manufacturing

Research data, genomics pipelines, and EHR integrations could be disrupted; 30-day notice would require emergency migration of bioinformatics workloads

Moderate API coupling risk in bioinformatics/genomics tools; core IP is proprietary cell engineering platform, not third-party API dependent

Standard equity/stock model; revenue from future drug sales/licensing; Howey Test not applicable—no token or investment contract structure

Very High

Clinical trial patient data subject to GDPR (EU trial sites) and HIPAA; CCPA exposure limited; compliance frameworks standard for pharma but resource-intensive

Low antitrust risk; early-stage single-asset pipeline; no market dominance; collaboration with Gilead raises no current competition concerns

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Pre-commercial; ~100% revenue from Gilead collaboration milestones and research funding—non-recurring milestone-gated payments, not subscription

Collaboration and license revenue from Gilead Sciences partnership; future monetization via drug sales royalties or additional licensing deals

No commercial pricing yet; future CAR-T therapy pricing likely $400K–$600K per patient course based on competitive benchmarks (e.g., Kymriah, Yescarta)

Moderate-high potential; CAR-T therapies command premium pricing with limited payer pushback given curative intent, but reimbursement risk is real

Commercial CAR-T therapies target 60–75% gross margin at scale; manufacturing cost reduction via allogeneic approach is a key value driver

No free-rider risk; proprietary cell therapy platform; IP moats and regulatory exclusivity limit leakage; collaboration terms restrict partner defection

Currently headcount-linear in R&D; scaling to commercialization requires significant manufacturing, medical affairs, and sales headcount additions—not sublinear

High marginal cost of growth; each additional patient treated requires substantial COGS in cell manufacturing; allogeneic model aims to reduce per-unit cost

null

At 10x scale, CAC would shift to hospital/cancer center contracting costs; patient identification and site activation are key bottlenecks, not traditional CAC

No meaningful network effects; cell therapy efficacy is independent of user base; data network effects possible via expanded patient outcome datasets

AI displacement risk low for core cell engineering; AI may accelerate target discovery and manufacturing QC but cannot replace GMP manufacturing processes

Moderate resilience; cancer treatment demand is largely inelastic, but high-cost cell therapies face reimbursement pressure during budget-constrained environments

Large pharma/biotech partners (Gilead Sciences represents dominant revenue concentration—likely >90% of current collaboration revenue)

Future: oncology patients (initially hematologic malignancies like NHL/leukemia) via hospital cancer centers and academic medical institutions

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

2166.7% CapEx / Revenue (High-CapEx Infrastructure)

0001806952

LYEL